The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This finding contrasts with prior observations relating polyclonal architecture to adverse clinical outcomes. Additionally, we utilized a novel approach to mutational signature analysis that leverages clonal architecture to uncover additional cases of homologous recombination and mismatch repair deficiency in primary and metastatic tumors and link the origin of mutational signatures to specific subclones. Broadly, prostate cancer clonal architecture analysis reveals novel biological insights that may be immediately clinically actionable and provide multiple opportunities for subsequent investigation.
Tumors from patients who self-reported as Black demonstrate linear and monoclonal evolutionary trajectories yet experience higher rates of biochemical recurrence. In addition, analysis of clonal and subclonal mutational signatures identifies additional tumors with potentially actionable alterations such as deficiencies in mismatch repair and homologous recombination.
bioRxiv : the preprint server for biology. 2023 Mar 25*** epublish ***
Jake R Conway, Alok K Tewari, Sabrina Y Camp, Seunghun Han, Jett Crowdis, Meng Xiao He, Yaw A Nyame, Saud H AlDubayan, Nikolaus Schultz, Zoltan Szallasi, Mark M Pomerantz, Matthew L Freedman, Lawrence Fong, Peter S Nelson, Myles Brown, Keyan Salari, Eliezer Van Allen